Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2020.0851
Abstract: Importance Use of biologic agents in generalized myasthenia gravis is generally limited to therapy-refractory cases; benefit in new-onset disease is unknown. Objective To assess rituximab in refractory and new-onset generalized myasthenia gravis and rituximab vs… read more here.
Keywords: generalized myasthenia; new onset; treatment; myasthenia gravis ... See more keywords
Causes of symptom dissatisfaction in patients with generalized myasthenia gravis
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10902-1
Abstract: Patient-centered assessments have attracted increasing attention in the last decade in clinics and research. The purpose of this study was to examine the association between patients’ satisfaction with symptoms and several disease-specific and generic outcome… read more here.
Keywords: patients generalized; dissatisfaction; generalized myasthenia; pass ... See more keywords
Eculizumab: A Review in Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0875-9
Abstract: The humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with… read more here.
Keywords: eculizumab review; generalized myasthenia; eculizumab; myasthenia gravis ... See more keywords
Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Neuromuscular Disease"
DOI: 10.1097/cnd.0000000000000219
Abstract: Objectives: To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody–positive generalized myasthenia gravis. Methods: In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status… read more here.
Keywords: generalized myasthenia; maintenance; myasthenia gravis; patients taking ... See more keywords
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
Sign Up to like & getrecommendations! Published in 2019 at "Neurology"
DOI: 10.1212/wnl.0000000000007600
Abstract: Objective To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were… read more here.
Keywords: myasthenia gravis; generalized myasthenia; gravis; study ... See more keywords